The seven women and five men who will determine the fate of notorious “pharma bro” Martin Shkreli began deliberations Monday morning.
The panel was officially handed the case at 9:40 a.m., as the anxious ex-pharmaceuticals exec looked on.
The 12 jurors will determine whether or not the 34-year-old is guilty of various charges of conspiracy to commit wire and securities fraud in what prosecutors described as a Ponzi scheme.
He faces up to 20 years behind bars if found guilty of the top charge of conspiracy to commit wire fraud, for allegedly orchestrating the $11 million scheme through his hedge fund, MSMB Capital.
The former CEO of Turing Pharmaceuticals — who became one of most hated men in America for jacking up the price of lifesaving AIDS drug Daraprim by more than 5,000 percent — allegedly paid off debts from MSMB and another failing hedge fund, as well as some personal expenses, by skimming assets from Retrophin, where he also served as chief executive.
Jurors — who hail from Brooklyn, Staten Island and Queens as well as Long Island — spent the last five weeks listening to an exhaustive stream of evidence against Shkreli.
High-priced defense attorneys Ben Brafman and Marc Agnifilo declined to call any witnesses.
The jurors include engineers, accountants and a pharmacist.